Increasing evidence shows that cancer cells can lose surface expression of TRAIL death receptors through a mechanism that is postulated to involve an accelerated DR4/DR5 endocytosis [13, 30] or insufficient receptor trafficking [31]. This evidence concerns the gene TNFRSF10A and cancer.